JUL 22, 2021 5:00 PM EDT

Closing Keynote Presentation Response to Second Generation CAR T Cell Therapy: It takes (at least) Two to Tango

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Professor, Pathology and Laboratory Medicine, University of Pennsylvania and Director, Biomarker Program, Parker Institute for Cancer Immunotherapy, UPenn
    BIOGRAPHY

Abstract

Though tumor targeting using chimeric receptors (CAR) engineered to bind tumor-associated surface proteins such as CD19 in B cells have demonstrated remarkable efficacy in cancer, this therapy has hit a glass ceiling w.r.t. initial and durable remissions. Inclusion of a costimulatory domain in the CAR design have solved much of limited clinical efficacy issues, some challenges remained. We have recently demonstrated that T cell-intrinsic mechanisms solved part of the glass ceiling conundrum in leukemia, we recently demonstrated that primary chronic lymphocytic leukemia cells elicit a blunted response of second generation CAR T cells, even when using normal donor CAR-engineered T cells. In my talk I will highlight our discoveries in T cell- and tumor-intrinsic determinants of anti-CD19 CAR T cell responses in this disease.

Learning Objectives:

1. Classify the Chimeric Antigen Receptor (CAR)-engineered T cells have dramatically altered the clinical outlook for many blood cancers

2. Identify that with the discovery of costimulation as a critical component of an effective T cell responses and the inclusion of such domains in CAR design we have overcome previous significant roadblocks, but encountered new challenges along the way

3. Recognize the part of what explains response and resistance to this therapy is T cell-intrinsic; however, even the most efficacious CAR showed ineffective against primary tumor cells

4. Summarize the highlights of some of our discoveries in elucidating T cell- and tumor-cell-intrinsic determinants of CAR T cell efficacy


Show Resources
You May Also Like
FEB 24, 2021 10:00 AM PST
C.E. CREDITS
FEB 24, 2021 10:00 AM PST
DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
MAR 30, 2021 8:00 AM PDT
MAR 30, 2021 8:00 AM PDT
DATE: March 30, 2021 TIME: 08:00am PST In this talk, we will discuss the value of moving towards modular and automated, closed-system technologies designed to enable scalable and cost-effect...
APR 21, 2021 10:00 AM PDT
C.E. CREDITS
APR 21, 2021 10:00 AM PDT
Date: April 21, 2021 Time: 10:00am (PDT), 1:00pm (EDT) Serological testing for SARS-CoV-2 has been steadily adopted into clinical practice over the course of this pandemic. In this webinar,...
APR 07, 2021 9:00 AM PDT
C.E. CREDITS
APR 07, 2021 9:00 AM PDT
One challenge pharmaceutical companies face, is moving promising biotherapeutic products into the clinic as fast as safely possible. Devoting the correct amount of time and resources to earl...
C.E. CREDITS
Parkinson’s disease (PD) is the second most common neurodegenerative disorder with multiple motor and non-motor symptoms. PD is characterized by the presence on proteinaceous neuronal...
Loading Comments...
Show Resources